Month: December 2024
-
Unprecedented major delay at USITC for remedy recommendation after Lenovo was found to infringe four Ericsson SEPs
While ITC judges typically issue their recommendations on remedy (i.e., U.S. import ban) near-simultaneously with their rulings, it will now potentially take more than two months in an Ericsson-Lenovo SEP case.
-
An interview with Johnson & Johnson’s departing VP of MedTech IP Strategy Paul Coletti
In this interview, Paul Coletti, (now former) VP of MedTech IP Strategy at Johnson & Johnson, shares the highlights of his 37 years in the company’s IP department, and the basis of successful leadership.
-
Huawei v. Netgear was only the second UPC anti-antisuit motion this month: a near-simultaneous one may have targeted Xiaomi
The UPC’s Munich LD has now published its December 11, 2024 anti-antisuit injunction in Huawei v. Netgear. It turns out that a similar motion was brought in a different case slightly before Huawei’s filing.
-
Abbott fends off Dexcom’s push for patent royalties as multi-jurisdictional litigation settles with 10-year zero-zero patent peace over glucose monitoring devices
Abbott and Dexcom have settled a multi-jurisdictional patent dispute over glucose monitoring devices. It appears that Dexcom failed to achieve its goal of getting Abbott to pay.
-
After almost 5 years of being sued by Broadcom, Netflix files U.S. countersuit over former HP virtualization patents: UPC filings to follow?
Context: In the early phase of the COVID-19 pandemic, Broadcom (Avago) started to sue Netflix over video streaming patents (March 14, 2020 Variety article). Para. 20 of the complaint (PDF) alleges that Broadcom’s business of selling “semiconductor chips used in the set top boxes that enable traditional cable television services” was substantially and irreparably harmed…
-
Netgear obeys UPC and German anti-antisuit injunctions, yet attempts to thwart Huawei’s patent enforcement through interim license
Netgear has withdrawn its request for a U.S. antisuit injunction against Huawei’s UPC and German cases, but keeps pursuing an interim license.
-
UPC’s Court of Appeal throws out Alexion’s appeals against Amgen and Samsung Bioepis over validity doubts, reveals €100M value of each dispute
The UPC’s Court of Appeal rejects Alexion’s appeals of decisions to deny preliminary injunctions against Amgen and Samsung Bioepis, where the value of the dispute was set at €100M for each case.
-
Japan’s Nippon Shinyaku vows to fight on in U.S. drug dispute against Sarepta Therapeutics, despite heavy $115 million blow
The Japanese pharma company initiated the drug patent litigation in 2021, but the case eventually boomeranged and a District of Delaware verdict last week ultimately handed Sarepta the win.
-
UPC responds to first antisuit attack on its jurisdiction with first anti-antisuit injunction against Netgear; Huawei also gets one from Munich I Regional Court
Context: Last week, the Unified Patent Court’s (UPC) Munich Local Division (LD) entered a final judgment, along with a permanent injunction, for Huawei and against Netgear (December 18, 2024 ip fray article). We subsequently explained the UPC’s FRAND (fair, reasonable and non-discriminatory licensing) reasoning (December 18, 2024 ip fray article) and reported on a trial that the Landgericht München…
-
Dutch government prepares major patent reform, switching from registration to examination system and strengthening climate tech
The Dutch government has started a public consultation for a major overhaul of its national patent law.